Tag Archive for: PARP inhibitor
AMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025